Clinical Trials for Loxo Oncology

Explore 17 clinical trials worldwide

Showing 1-17 of 17 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Loxo Oncology

Clinical Trials (17)

NCT06588478
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
PHASE2Recruiting
249 participants
Started: Jan 3, 2025 · Completed: Dec 31, 2028
2 conditions2 sponsors135 locations
NCT06333262
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
PHASE2Active, not recruiting
60 participants
Started: Apr 22, 2024 · Completed: Feb 1, 2029
2 conditions2 sponsors4 locations
NCT06043674
A Ph2 Study of Glofitamab Alone or With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
PHASE2Recruiting
70 participants
Started: Jan 22, 2024 · Completed: Jan 15, 2033
2 conditions4 sponsors4 locations
NCT05529069
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
PHASE2Recruiting
30 participants
Started: Jan 25, 2023 · Completed: Apr 28, 2027
3 conditions2 sponsors1 location
NCT05536349
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
PHASE2Recruiting
60 participants
Started: Dec 20, 2022 · Completed: Apr 25, 2028
1 condition3 sponsors1 location
NCT05254743
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
PHASE3Recruiting
662 participants
Started: Jul 22, 2022 · Completed: Jan 31, 2028
4 conditions1 sponsor148 locations
NCT04819100
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
PHASE3Active, not recruiting
152 participants
Started: Dec 20, 2021 · Completed: May 31, 2028
1 condition2 sponsors211 locations
NCT05023980
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
PHASE3Active, not recruiting
309 participants
Started: Sep 23, 2021 · Completed: Aug 31, 2026
2 conditions2 sponsors108 locations
NCT04965493
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
PHASE3Active, not recruiting
600 participants
Started: Sep 20, 2021 · Completed: Jan 31, 2027
2 conditions2 sponsors176 locations
NCT04849416
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
PHASE2Active, not recruiting
87 participants
Started: May 14, 2021 · Completed: Dec 31, 2025
7 conditions2 sponsors22 locations
NCT04662255
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
PHASE3Active, not recruiting
500 participants
Started: Apr 8, 2021 · Completed: Apr 30, 2028
1 condition2 sponsors189 locations
NCT04666038
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
PHASE3Active, not recruiting
238 participants
Started: Mar 9, 2021 · Completed: May 31, 2027
2 conditions2 sponsors232 locations
NCT04194944
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
PHASE3Active, not recruiting
261 participants
Started: Feb 17, 2020 · Completed: Jun 30, 2030
1 condition2 sponsors196 locations
NCT04211337
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
PHASE3Active, not recruiting
291 participants
Started: Feb 11, 2020 · Completed: Feb 28, 2026
1 condition2 sponsors143 locations
NCT03899792
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
PHASE1/PHASE2Active, not recruiting
50 participants
Started: Jun 13, 2019 · Completed: May 31, 2029
5 conditions2 sponsors26 locations
NCT03740529
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
PHASE1/PHASE2Active, not recruiting
860 participants
Started: Mar 15, 2019 · Completed: Sep 30, 2027
6 conditions2 sponsors56 locations
NCT03157128
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
PHASE1/PHASE2Active, not recruiting
857 participants
Started: May 2, 2017 · Completed: Feb 28, 2027
4 conditions2 sponsors85 locations